MCID: HYP063
MIFTS: 51

Hypersplenism

Categories: Blood diseases, Immune diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hypersplenism

MalaCards integrated aliases for Hypersplenism:

Name: Hypersplenism 11 53 43 14 16 71 75 31 33
Hypersplenia 11 33
Increased Splenic Activity 33
Hyperfunction of Spleen 33
Big Spleen Syndrome 33
Splenic Metaplasia 33
Spleen Metaplasia 33

Classifications:



External Ids:

Disease Ontology 11 DOID:6376
ICD9CM 34 289.4
MeSH 43 D006971
NCIt 49 C34714
SNOMED-CT 68 154839008
ICD10 31 D73.1
ICD11 33 2093549625
UMLS 71 C0020532

Summaries for Hypersplenism

MalaCards based summary: Hypersplenism, also known as hypersplenia, is related to purpura and thrombocytopenic purpura, autoimmune. An important gene associated with Hypersplenism is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are TGF-Beta Pathway and MIF Mediated Glucocorticoid Regulation. The drugs Warfarin and Acetylsalicylic acid have been mentioned in the context of this disorder. Affiliated tissues include spleen, bone marrow and bone, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Wikipedia: 75 Splenomegaly is an enlargement of the spleen. The spleen usually lies in the left upper quadrant (LUQ)... more...

Related Diseases for Hypersplenism

Diseases related to Hypersplenism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 570)
# Related Disease Score Top Affiliating Genes
1 purpura 30.6 THPO SERPINC1 F2
2 thrombocytopenic purpura, autoimmune 30.5 THPO F2 CD4
3 sickle cell anemia 30.4 SERPINC1 F2 EPO CSF3 CD4 ALB
4 liver cirrhosis 30.4 THPO SERPINC1 GPT F2 ALB AFP
5 aplastic anemia 30.4 U2AF1 THPO EPO CSF3 CSF2 CD4
6 thalassemia 30.4 GPT F2 EPO ALB
7 thrombocytopenia due to platelet alloimmunization 30.4 U2AF1 THPO CD4
8 schistosomiasis 30.4 GPT F2 ALB
9 wilson disease 30.3 GPT F2 ALB
10 anemia, autoimmune hemolytic 30.3 FOXP3 EPO CD4
11 peritonitis 30.3 TLR4 F2 CSF3 ALB
12 splenic tuberculosis 30.3 F2 CD4 ALB
13 granulocytopenia 30.3 CSF3 CSF2
14 splenic infarction 30.2 U2AF1 SERPINC1 GPT F2 ALB
15 endocarditis 30.2 SERPINC1 F2 ALB
16 hepatic encephalopathy 30.2 GPT F2 ALB
17 paralytic ileus 30.2 GPT F2 ALB
18 biliary atresia 30.2 GPT F2 ALB
19 felty syndrome 30.2 U2AF1 CSF3 CSF2
20 toxic shock syndrome 30.1 TLR4 SERPINC1 CSF3
21 beta-thalassemia 30.1 SERPINC1 GPT F2 EPO
22 splenic abscess 30.1 THPO GPT F2 CD4 ALB
23 portal hypertension 30.1 THPO PKHD1 GPT F2 ALB AFP
24 miliary tuberculosis 30.0 GPT CD4 ALB
25 aphthous stomatitis 30.0 CSF3 CD4 ALB
26 dysentery 30.0 TLR4 CD4 ALB
27 cavernous hemangioma 30.0 SERPINC1 F2 ALB AFP
28 klippel-trenaunay-weber syndrome 30.0 SERPINC1 PIK3R1 F2
29 portal vein thrombosis 29.9 THPO SERPINC1 GPT F2 ALB AFP
30 splenic sequestration 29.9 U2AF1 THPO F2 EPO CD4 ALB
31 peripheral vascular disease 29.9 SERPINC1 F2 EPO ALB
32 crohn's disease 29.9 TLR4 FOXP3 CSF2 CD4 ALB
33 myelofibrosis 29.9 U2AF1 THPO IL2RA EPO CSF3
34 sleep apnea 29.9 GPT EPO ALB
35 acquired immunodeficiency syndrome 29.9 IL2RA EPO CSF2 CD4 ALB
36 adult t-cell leukemia/lymphoma 29.8 IL2RA FOXP3 CD4
37 volvulus of midgut 29.8 GPT F2 ALB
38 choledocholithiasis 29.8 GPT F2 ALB
39 beta-thalassemia major 29.8 GPT EPO ALB
40 lymphoma, non-hodgkin, familial 29.7 U2AF1 IL2RA CSF3 CSF2 CD4
41 disseminated intravascular coagulation 29.7 SERPINC1 GPT F2
42 cholangitis 29.7 TLR4 GPT F2 ALB
43 syphilis 29.6 GPT FOXP3 CD4 ALB
44 neutropenia 29.6 TLR4 THPO GPT EPO CSF3 CSF2
45 systemic mastocytosis 29.6 U2AF1 PIK3R1 IL2RA
46 autoimmune hepatitis 29.6 GPT FOXP3 F2 ALB
47 lymphoma, hodgkin, classic 29.6 REL IL2RA CSF3 CSF2
48 hepatitis b 29.6 TLR4 GPT F2 ALB AFP
49 hemoglobinuria 29.6 THPO SERPINC1 F2 EPO CSF3
50 cystic fibrosis 29.6 TLR4 EGF CSF3 CSF2 CD4 ALB

Comorbidity relations with Hypersplenism via Phenotypic Disease Network (PDN): (show all 12)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Alcoholic Liver Cirrhosis
Chronic Congestive Splenomegaly Deficiency Anemia
Heart Disease Hepatic Encephalopathy
Iron Deficiency Anemia Neutropenia
Portal Hypertension Primary Thrombocytopenia

Graphical network of the top 20 diseases related to Hypersplenism:



Diseases related to Hypersplenism

Symptoms & Phenotypes for Hypersplenism

GenomeRNAi Phenotypes related to Hypersplenism according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.14 AFP ALB CD4 CSF2 CSF3 EGF
2 no effect GR00402-S-2 10.14 ALB CD4 CSF2 CSF3 EGF EPO
3 Reduced mammosphere formation GR00396-S 9.5 AFP ALB CSF3 IL2RA PIK3R1 SERPINC1

MGI Mouse Phenotypes related to Hypersplenism:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 AFP ALB CD4 CSF2 EPO F2
2 immune system MP:0005387 10.28 ALB CD4 CSF2 CSF3 EGF EPO
3 endocrine/exocrine gland MP:0005379 10.23 AFP ALB CD4 CSF2 EGF F2
4 cellular MP:0005384 10.22 ALB CD4 CSF2 EPO F2 FOXP3
5 normal MP:0002873 10.21 ALB EGF F2 FOXP3 IL7R PIK3R1
6 liver/biliary system MP:0005370 10.19 AFP ALB EPO FOXP3 PIK3R1 PKHD1
7 cardiovascular system MP:0005385 10.18 ALB CSF2 EPO F2 FOXP3 IL2RA
8 digestive/alimentary MP:0005381 10.13 ALB CD4 EGF F2 FOXP3 IL2RA
9 neoplasm MP:0002006 10.07 AFP ALB CSF2 IL7R PIK3R1 TLR4
10 hematopoietic system MP:0005397 10.06 CD4 CSF2 CSF3 EPO F2 FOXP3
11 respiratory system MP:0005388 9.96 CSF2 EPO F2 FOXP3 IL2RA PKHD1
12 mortality/aging MP:0010768 9.8 ALB CD4 CSF2 EPO F2 FOXP3
13 integument MP:0010771 9.36 CD4 CSF2 CSF3 EGF F2 FOXP3

Drugs & Therapeutics for Hypersplenism

Drugs for Hypersplenism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Warfarin Approved Phase 4 81-81-2, 129-06-6 54678486
2
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
3
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
4
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
5
Dipyridamole Approved Phase 4 58-32-2 3108
6
Nadroparin Approved, Investigational Phase 4
7
Reviparin Approved, Investigational Phase 4 9041-08-1
8 Liver Extracts Phase 4
9 Analgesics Phase 4
10 Antirheumatic Agents Phase 4
11 Fibrinolytic Agents Phase 4
12 Antipyretics Phase 4
13 Phosphodiesterase Inhibitors Phase 4
14 Vasodilator Agents Phase 4
15 Cyclooxygenase Inhibitors Phase 4
16 Platelet Aggregation Inhibitors Phase 4
17 Calcium, Dietary Phase 4
18 Anti-Inflammatory Agents, Non-Steroidal Phase 4
19 Anticoagulants Phase 4
20 Analgesics, Non-Narcotic Phase 4
21 Anti-Inflammatory Agents Phase 4
22 Heparin, Low-Molecular-Weight Phase 4
23
Calcium Nutraceutical Phase 4 7440-70-2 271
24
Valproic acid Approved, Investigational Phase 1, Phase 2 99-66-1 3121
25 Neurotransmitter Agents Phase 1, Phase 2
26 Psychotropic Drugs Phase 1, Phase 2
27 Anticonvulsants Phase 1, Phase 2
28
Propranolol Approved, Investigational 318-98-9, 525-66-6 62882 4946
29
Heparin, bovine Approved, Investigational, Withdrawn 9005-49-6 22833565 9812414 772
30
Verapamil Approved 152-11-4, 52-53-9 2520
31
Nitroglycerin Approved, Investigational 55-63-0 4510
32
Somatostatin Approved, Investigational 38916-34-6, 51110-01-1 53481605 16129706
33
Carvedilol Approved, Investigational 72956-09-3 2585
34 Calcium heparin
35 Anesthetics
36 Sclerosing Solutions
37 Adrenergic beta-Antagonists
38 Adrenergic Antagonists
39 Adrenergic Agents
40 Hormones
41 Hormone Antagonists

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Unknown status NCT02238444 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
2 Pilot (Phase I-II) Study of Valproic Acid (Depakote) for the Treatment of the Autoimmune Lymphoproliferative Syndrome (ALPS) Completed NCT00605657 Phase 1, Phase 2 Valproic Acid
3 Comparative Study of Microwave Ablation and Partial Splenic Embolization in the Management of Hypersplenism Unknown status NCT02261584
4 Hypersplenism in Patients With Liver Cirrhosis and Portal Hypertension: Prevalence, Pattern, Correlations, and Therapy Unknown status NCT03269877
5 Multicentric Retrospective Case Control Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis Unknown status NCT01201655
6 Partial Splenic Embolization Combined With Endoscopic Therapies and NSBB Decreases the Variceal Rebleeding Rate in Cirrhosis Patients With Hypersplenism: a Multicenter Randomized Controlled Trial Completed NCT02778425
7 Transfemoral Versus Transradial Partial Splenic Artery Embolization in Patients With Hypersplenism, a Randomized Controlled Trial Completed NCT05446116
8 EUS-guided Partial Splenic Embolization in Combination With EUS-guided Treatment of Varices for Patients With Portal Hypertension Recruiting NCT04692805 cyanoacrylate glue
9 The Effects of Endoscopy Combined With Partial Splenic Artery Embolization in the Treatment of Cirrhosis With Esophageal and Gastric Varices Complicated With Hyperplenism or Splenomegaly:A Randomized Controlled Study. Enrolling by invitation NCT05055713

Search NIH Clinical Center for Hypersplenism

Cochrane evidence based reviews: hypersplenism

Genetic Tests for Hypersplenism

Anatomical Context for Hypersplenism

Organs/tissues related to Hypersplenism:

MalaCards : Spleen, Bone Marrow, Bone, Liver, Kidney, Myeloid, Pineal

Publications for Hypersplenism

Articles related to Hypersplenism:

(show top 50) (show all 2231)
# Title Authors PMID Year
1
Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection. 53 62
16215425 2005
2
Platelet count increase following phlebotomy in iron overloaded patients with liver cirrhosis. 53 62
12911944 2003
3
Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver diseases. 53 62
12753144 2003
4
Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. 53 62
12399221 2002
5
Role of plasma thrombopoietin level in thrombocytopenia of postoperative biliary atresia patients. 53 62
12149701 2002
6
Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma. 53 62
11787473 2000
7
Thrombocytopenia associated with liver cirrhosis and hepatitis C viral infection: role of thrombopoietin. 53 62
11100362 2000
8
Laparoscopic cholecystectomy for cholelithiasis in patients with liver cirrhosis. 53 62
18493357 1995
9
Open Radiofrequency Ablation Combined with Splenectomy and Pericardial Devascularization vs. Liver Transplantation for Hepatocellular Carcinoma Patients with Portal Hypertension and Hypersplenism: A Case-Matched Comparative Study. 62
36345736 2023
10
Early prevention and risk factors analysis of portal vein system thrombosis after laparoscopic splenectomy and pericardial devascularization. 62
35764840 2022
11
Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis. 62
35301618 2022
12
Hypersplenism and thrombocytopenia after exposure to ustekinumab in a patient with Crohn's disease. 62
36229348 2022
13
Minimally invasive treatment of cirrhotic secondary hypersplenism with high-intensity focused ultrasound. 62
36450808 2022
14
Successful Steroid Treatment of Pembrolizumab-induced Agranulocytosis that Developed after Splenectomy in a Patient with Non-small-cell Lung Cancer: A Case Report. 62
36450461 2022
15
Primary splenic T-cell/histiocyte-rich B-cell lymphoma in a patient with recurrent hairy cell leukemia: a case report. 62
36447474 2022
16
Non-alcoholic fatty liver disease and thrombocytopenia IV: its association with granulocytopenia. 62
34312112 2022
17
MPN-352 Clinicopathologic and Molecular Correlates of Organ Damage Across the Spectrum of Advanced Systemic Mastocytosis. 62
36164002 2022
18
Hypersplenism caused by Caroli's disease. 62
36253263 2022
19
Robotic-assisted versus laparoscopic approach of Bai-Jiang-style vagus nerve-preserving splenectomy and azygoportal disconnection. 62
34994944 2022
20
Clinical effects of cluster technology optimization and innovations on laparoscopic splenectomy and azygoportal disconnection: a single-center retrospective study with 500 consecutive cases. 62
35257212 2022
21
Successful Preoperative Partial Splenic Artery and Aneurysm Embolization for Thrombocytopenia Associated with Failed Fontan Circulation. 62
36104230 2022
22
Vagus Nerve-Preserving Laparoscopic Splenectomy and Azygoportal Disconnection with Versus Without Intraoperative Endoscopic Variceal Ligation: a Randomized Clinical Trial. 62
35676457 2022
23
Splenic artery aneurysm with extrahepatic portal venous obstruction: A case report. 62
36380538 2022
24
Early post-liver transplant thrombocytopenia in children: Clinical characteristics and significance. 62
35599548 2022
25
Efficacy and safety of splenic artery embolization for intractable ascites using Amplatzer vascular plug versus coil after living donor liver transplantation. 62
36218150 2022
26
Determination of etiology in patients admitted due to isolated leukopenia. 62
35984149 2022
27
The prevalence of sickling abnormality in Oman: A review of relevant publications 62
36043956 2022
28
Comparison of thrombocytopenia between patients with non-alcoholic fatty liver disease and those with hepatitis C virus-related chronic liver disease. 62
35543116 2022
29
Management of Patients with Alagille Syndrome Undergoing Living Donor Liver Transplantation: A Report of 2 Cases. 62
35921256 2022
30
Efficacy of interventional radiology in the management of portal hypertension: A narrative review. 62
35984127 2022
31
Predicting the risk of postsplenectomy thrombosis in patients with portal hypertension using computational hemodynamics models: A proof-of-concept study. 62
35834965 2022
32
Development of an Eye-Tracking Image Manipulation System for Angiography: A Comparative Study. 62
33158704 2022
33
Cystic fibrosis-related liver disease is an independent risk factor for mortality and increased health care resource utilization in hospitalized pediatric patients with cystic fibrosis. 62
35499220 2022
34
Improvement of SLC29A3 spectrum disorder-related sensorineural hearing loss after initiation of IL-6 inhibitor. 62
35732371 2022
35
Clinico-pathological profile of pancytopenia patients in a single health care centre of northern India. 62
36119319 2022
36
Partial splenectomy in children undergoing liver transplantation or venous shunt for severe hypersplenism: A case control comparative study. 62
35462062 2022
37
Interaction of aging with lipoxygenase deficiency initiates hypersplenism, cardiac dysfunction, and profound leukocyte directed non-resolving inflammation. 62
34932185 2022
38
Porto-Sinusoidal Vascular Disease: A Pediatric Study of 30 Patients. 62
35258501 2022
39
An updated meta-analysis of partial splenic embolization versus splenectomy in the treatment of hypersplenism due to cirrhosis. 62
34106805 2022
40
Primary splenic lymphoma discovered on massive splenomegaly: A case report. 62
35658295 2022
41
[Clinical characteristics of 500 hospitalized patients with liver cirrhosis: a retrospective analysis from a tertiary hospital in Beijing]. 62
35764547 2022
42
Successful use of a mesocaval shunt to treat refractory ascites in a chronic pancreatitis induced portal vein thrombosis. 62
35193995 2022
43
Gastro-colic Fistula-associated Hypersplenism Causes Pancytopenia in a Patient with Crohn's Disease: A Case Report. 62
35598997 2022
44
Spectrum of Pancytopenia in Adults Attending a Clinical Hematology Department: A Four-Year Experience From a Tertiary Care Center of Western India. 62
35706755 2022
45
Elective splenectomy in patients with non-Hodgkin lymphoma: Does the size of the spleen affect surgical outcomes? 62
35168206 2022
46
Clinical and Haematological Abnormalities in Decompensated Chronic Liver Disease Patients. 62
35443528 2022
47
Limits in Laparoscopic Partial Splenectomy in Children. 62
35626782 2022
48
National Consensus on Portal Hypertension Management in Indonesia. 62
35818657 2022
49
Portal Steal Syndrome From a Large Linton's Splenorenal Shunt after Liver Transplantation: Successful Endovascular Management Through Off-Label Application of a 30 mm Amplatzer Cardiac Plug. 62
34978227 2022
50
Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension. 62
35272246 2022

Variations for Hypersplenism

Expression for Hypersplenism

Search GEO for disease gene expression data for Hypersplenism.

Pathways for Hypersplenism

Pathways related to Hypersplenism according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.52 THPO PIK3R1 IL7R IL2RA F2 EPO
2
Show member pathways
13.41 TLR4 RELA PIK3R1 IL7R IL2RA F2
3
Show member pathways
13.28 RELA PIK3R1 IL7R IL2RA CSF3 CSF2
4
Show member pathways
13.17 TLR4 THPO PIK3R1 IL7R IL2RA EGF
5
Show member pathways
13.16 THPO PIK3R1 IL7R IL2RA EGF CSF3
6
Show member pathways
12.85 THPO RELA PIK3R1 IL7R IL2RA
7
Show member pathways
12.63 RELA REL PIK3R1 EGF CD4
8
Show member pathways
12.57 THPO PIK3R1 IL7R IL2RA EPO EGF
9
Show member pathways
12.56 TLR4 RELA PIK3R1 IL7R IL2RA EPO
10
Show member pathways
12.53 CD4 F2 PIK3R1 REL RELA
11
Show member pathways
12.53 TLR4 THPO RELA REL PIK3R1 EGF
12
Show member pathways
12.48 EGF PIK3R1 REL RELA
13
Show member pathways
12.4 TLR4 RELA REL PIK3R1
14
Show member pathways
12.35 SERPINC1 F2 ALB AFP
15
Show member pathways
12.29 CD4 PIK3R1 REL RELA
16
Show member pathways
12.24 RELA REL CSF3 CSF2
17
Show member pathways
12.1 RELA PIK3R1 CSF2 CD4
18
Show member pathways
12.08 RELA REL PIK3R1 EGF
19 12.01 THPO EGF ALB AFP
20 11.99 TLR4 RELA REL PIK3R1
21
Show member pathways
11.94 FOXP3 IL2RA PIK3R1 RELA
22
Show member pathways
11.93 IL2RA PIK3R1 RELA TLR4
23
Show member pathways
11.86 RELA REL IL2RA CD4
24 11.78 IL7R IL2RA CD4
25 11.76 RELA CSF2 AFP
26 11.75 TLR4 PIK3R1 CD4
27 11.73 IL7R CSF2 CD4
28 11.7 IL2RA FOXP3 CD4
29
Show member pathways
11.68 IL2RA FOXP3 CSF2
30
Show member pathways
11.64 RELA REL CSF2
31 11.64 EGF CSF3 CSF2
32 11.63 TLR4 RELA REL
33 11.57 TLR4 RELA CD4
34 11.56 EGF IL2RA PIK3R1
35 11.55 REL RELA TLR4
36
Show member pathways
11.53 RELA REL PIK3R1 EGF
37 11.48 IL2RA FOXP3 CD4
38 11.47 RELA REL IL2RA CD4
39
Show member pathways
11.44 F2 ALB AFP
40 11.43 TLR4 RELA REL
41
Show member pathways
11.4 TLR4 RELA REL FOXP3 CSF3 CSF2
42 11.35 TLR4 RELA REL PIK3R1
43
Show member pathways
11.33 IL2RA FOXP3 CSF2
44 11.23 THPO IL7R IL2RA EPO CSF3 CSF2
45 11.16 CSF3 CSF2 CD4
46
Show member pathways
11.08 IL2RA PIK3R1 REL RELA
47 11.01 THPO PIK3R1 EGF CSF3 CSF2
48 10.98 TLR4 RELA REL
49 10.75 TLR4 RELA
50 10.7 IL2RA FOXP3

GO Terms for Hypersplenism

Cellular components related to Hypersplenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.36 TLR4 PKHD1 IL7R IL2RA F2 CD4
2 NF-kappaB complex GO:0071159 9.26 RELA REL

Biological processes related to Hypersplenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 10 CD4 CSF2 CSF3 IL2RA IL7R PIK3R1
2 cellular response to lipopolysaccharide GO:0071222 9.96 TLR4 THPO RELA CSF3 CSF2
3 T cell differentiation GO:0030217 9.8 PIK3R1 IL7R CD4
4 T cell homeostasis GO:0043029 9.77 IL7R IL2RA FOXP3
5 positive regulation of cell population proliferation GO:0008284 9.58 THPO RELA PKHD1 IL7R F2 EPO
6 negative regulation of lymphocyte proliferation GO:0050672 9.43 IL2RA FOXP3
7 negative regulation of macromolecule metabolic process GO:0010605 9.32 RELA REL
8 lymphocyte proliferation GO:0046651 9.13 TLR4 IL2RA FOXP3

Molecular functions related to Hypersplenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.32 THPO F2 EGF CSF3 CSF2

Sources for Hypersplenism

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....